Christina K Speirs1, Todd A DeWees1, Sana Rehman1, Alerson Molotievschi2, Maria A Velez1, Daniel Mullen1, Sandra Fergus1, Marco Trovo3, Jeffrey D Bradley1, Cliff G Robinson4. 1. Department of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri. 2. Clinicas Oncologicas Integradas, Rio de Janeiro, Brazil. 3. Department of Radiation Oncology, Centro di Referimento Oncologico Aviano, Aviano, Italy. 4. Department of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri. Electronic address: crobinson@radonc.wustl.edu.
Abstract
INTRODUCTION: In the randomized trial of standard- versus high-dose chemoradiotherapy for locally advanced (LA) NSCLC (Radiation Therapy Oncology Group 0617), overall survival (OS) was worse in the high-dose arm. Although heart dose was suggested as a contributing factor, actionable parameters have not been established. We present an analysis of clinical and dosimetric parameters affecting OS in this patient population, focusing on heart dose. METHODS: Clinical data were collected on 416 patients with LA NSCLC treated at a single institution, with a subset of 333 available treatment plans recontoured using Radiation Therapy Oncology Group 0617 normal tissue guidelines. Toxicity and dosimetry data were analyzed for 322 patients; multivariate analysis was performed on 251 patients. Dosimetric parameters of radiation to tumor and organs at risk were analyzed with clinical data pertaining to OS, disease-free survival, and toxicity. RESULTS: Patients were treated with radiation therapy to prescribed doses of 50.0 to 84.9 Gy (median 66.0 Gy). Median follow-up was 14.5 months. Median OS was 16.8 months. The 1- and 2-year OS rates were 61.4% and 38.8%, respectively. On multivariate analysis, factors independently associated with worse OS were increasing heart V50 (volume receiving ≥50 Gy), heart volume, lung V5 (proportion of the lung structure [excluding the target volume]) receiving at least 5 Gy), bilateral mediastinal lymph node involvement, and lack of concurrent chemotherapy. When stratified by heart V50 less than 25% versus 25% or greater, the 1-year OS rates were 70.2% versus 46.8% and the 2-year OS rates were 45.9% versus 26.7% (p < 0.0001). Median heart V50 was significantly higher (20.8% versus 13.9%, p < 0.0001) for patients with cardiac toxicity with a Common Terminology Criteria for Adverse Events grade of 1 or higher. CONCLUSIONS: Heart dose is associated with OS and cardiac toxicity for patients with LA NSCLC treated withchemoradiotherapy.
RCT Entities:
INTRODUCTION: In the randomized trial of standard- versus high-dose chemoradiotherapy for locally advanced (LA) NSCLC (Radiation Therapy Oncology Group 0617), overall survival (OS) was worse in the high-dose arm. Although heart dose was suggested as a contributing factor, actionable parameters have not been established. We present an analysis of clinical and dosimetric parameters affecting OS in this patient population, focusing on heart dose. METHODS: Clinical data were collected on 416 patients with LA NSCLC treated at a single institution, with a subset of 333 available treatment plans recontoured using Radiation Therapy Oncology Group 0617 normal tissue guidelines. Toxicity and dosimetry data were analyzed for 322 patients; multivariate analysis was performed on 251 patients. Dosimetric parameters of radiation to tumor and organs at risk were analyzed with clinical data pertaining to OS, disease-free survival, and toxicity. RESULTS:Patients were treated with radiation therapy to prescribed doses of 50.0 to 84.9 Gy (median 66.0 Gy). Median follow-up was 14.5 months. Median OS was 16.8 months. The 1- and 2-year OS rates were 61.4% and 38.8%, respectively. On multivariate analysis, factors independently associated with worse OS were increasing heart V50 (volume receiving ≥50 Gy), heart volume, lung V5 (proportion of the lung structure [excluding the target volume]) receiving at least 5 Gy), bilateral mediastinal lymph node involvement, and lack of concurrent chemotherapy. When stratified by heart V50 less than 25% versus 25% or greater, the 1-year OS rates were 70.2% versus 46.8% and the 2-year OS rates were 45.9% versus 26.7% (p < 0.0001). Median heart V50 was significantly higher (20.8% versus 13.9%, p < 0.0001) for patients with cardiac toxicity with a Common Terminology Criteria for Adverse Events grade of 1 or higher. CONCLUSIONS: Heart dose is associated with OS and cardiac toxicity for patients with LA NSCLC treated with chemoradiotherapy.
Authors: Yevgeniy Vinogradskiy; Quentin Diot; Bernard Jones; Richard Castillo; Edward Castillo; Jennifer Kwak; Daniel Bowles; Inga Grills; Nicholas Myziuk; Thomas Guerrero; Craig Stevens; Tracey Schefter; Laurie E Gaspar; Brian Kavanagh; Moyed Miften; Chad Rusthoven Journal: Int J Radiat Oncol Biol Phys Date: 2020-01-23 Impact factor: 7.038
Authors: Peter G Hawkins; Yilun Sun; Robert T Dess; William C Jackson; Grace Sun; Nan Bi; Muneesh Tewari; James A Hayman; Gregory P Kalemkerian; Shirish M Gadgeel; Theodore S Lawrence; Randall K Ten Haken; Martha M Matuszak; Feng-Ming Spring Kong; Matthew J Schipper; Shruti Jolly Journal: J Cancer Res Clin Oncol Date: 2019-03-28 Impact factor: 4.553
Authors: Matthew J Ferris; Katherine S Martin; Jeffrey M Switchenko; Oluwatosin A Kayode; Jonathan Wolf; Quang Dang; Robert H Press; Walter J Curran; Kristin A Higgins Journal: Pract Radiat Oncol Date: 2019-05-09
Authors: Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong Journal: Transl Lung Cancer Res Date: 2017-12
Authors: Joe Y Chang; Vivek Verma; Ming Li; Wencheng Zhang; Ritsuko Komaki; Charles Lu; Pamela K Allen; Zhongxing Liao; James Welsh; Steven H Lin; Daniel Gomez; Melenda Jeter; Michael O'Reilly; Ronald X Zhu; Xiaodong Zhang; Heng Li; Radhe Mohan; John V Heymach; Ara A Vaporciyan; Stephen Hahn; James D Cox Journal: JAMA Oncol Date: 2017-08-10 Impact factor: 31.777
Authors: Chenbin Liu; Steven E Schild; Joe Y Chang; Zhongxing Liao; Shawn Korte; Jiajian Shen; Xiaoning Ding; Yanle Hu; Yixiu Kang; Sameer R Keole; Terence T Sio; William W Wong; Narayan Sahoo; Martin Bues; Wei Liu Journal: Int J Radiat Oncol Biol Phys Date: 2018-02-14 Impact factor: 7.038
Authors: Cai Xu; Jian-Yue Jin; Ming Zhang; Amy Liu; Jun Wang; Radhe Mohan; Fengming Spring Kong; Steven H Lin Journal: Radiother Oncol Date: 2020-03-19 Impact factor: 6.280
Authors: Maria Thor; Joseph O Deasy; Chen Hu; Elizabeth Gore; Voichita Bar-Ad; Clifford Robinson; Matthew Wheatley; Jung Hun Oh; Jeffrey Bogart; Yolanda I Garces; Vivek S Kavadi; Samir Narayan; Puneeth Iyengar; Jacob S Witt; James W Welsh; Cristopher D Koprowski; James M Larner; Ying Xiao; Jeffrey Bradley Journal: Clin Cancer Res Date: 2020-05-12 Impact factor: 12.531